Clinical profile and outcome of patients with breast cancer and bone marrow metastasis (BMM) at the Brazilian National Cancer Institute (INCA).

Abstract

e11515 Background: Breast cancer (BC) is the second most common cancer in the world. Advanced disease is associated with worse prognosis, especially when visceral metastasis are diagnosed. The objective of this study is to evaluate the clinical characteristics and outcome of pts with BC and BMM. Methods: Retrospective chart review of clinical data from pts with BC and histopathological confirmation of BMM treated at the Brazilian National Cancer Institute between 1996 and 2008. Results: Clinical data was available from 88 consecutive pts. All pts had cytopenias, and this was the clinical indication for the BM biopsy. Median age at diagnosis of BC was 53y (33-72); median interval between BC and BMM diagnosis was 35 months (0-85). Infiltrating ductal carcinoma represented 84.4% of cases, infiltrating lobular carcinoma 8.8%, mucinous carcinoma 5.5%, and mixed tumor histology 1%; histological grade I 3.3%, 22.2% in II and III in 15.5% (59% not rated); hormone receptor was positive in 64.4%, negative in 23.3%; stage at diagnosis: 35.5% stage IV, 32.2% IIIB, 36.6% IIIA, 5.5% IIB, 4.4% II. When BMM was diagnosed, 90% had bone metastasis, 36.6% had liver metastasis, 26.6% skin, 10% pleural/lung, 10% central nervous system. Most pts received treatment after the diagnosis of BMM: 31% chemotherapy, 8.8% endocrine therapy, 18.8% chemo and endocrine therapy. Median overall survival after the BMM diagnosis: 16 weeks (0-480). Conclusions: BMM was associated with advanced disease and poor overall survival. No significant financial relationships to disclose.